121 related articles for article (PubMed ID: 33087508)
21. MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model.
Bartholomeusz C; Oishi T; Saso H; Akar U; Liu P; Kondo K; Kazansky A; Krishnamurthy S; Lee J; Esteva FJ; Kigawa J; Ueno NT
Mol Cancer Ther; 2012 Feb; 11(2):360-9. PubMed ID: 22144664
[TBL] [Abstract][Full Text] [Related]
22. MEK Is a Therapeutic and Chemopreventative Target in Squamous Cell Carcinoma.
Adelmann CH; Truong KA; Liang RJ; Bansal V; Gandee L; Saporito RC; Lee W; Du L; Nicholas C; Napoli M; Mino B; South AP; Proby CM; Leigh IM; Coarfa C; Flores ER; Tsai KY
J Invest Dermatol; 2016 Sep; 136(9):1920-1924. PubMed ID: 27293029
[No Abstract] [Full Text] [Related]
23. Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer.
Pitts TM; Newton TP; Bradshaw-Pierce EL; Addison R; Arcaroli JJ; Klauck PJ; Bagby SM; Hyatt SL; Purkey A; Tentler JJ; Tan AC; Messersmith WA; Eckhardt SG; Leong S
PLoS One; 2014; 9(11):e113037. PubMed ID: 25401499
[TBL] [Abstract][Full Text] [Related]
24. Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.
Wong MH; Xue A; Baxter RC; Pavlakis N; Smith RC
Neoplasia; 2016 Jul; 18(7):425-35. PubMed ID: 27435925
[TBL] [Abstract][Full Text] [Related]
25. MEK inhibition suppresses B regulatory cells and augments anti-tumor immunity.
Yarchoan M; Mohan AA; Dennison L; Vithayathil T; Ruggieri A; Lesinski GB; Armstrong TD; Azad NS; Jaffee EM
PLoS One; 2019; 14(10):e0224600. PubMed ID: 31671149
[TBL] [Abstract][Full Text] [Related]
26. Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer.
Naderi A; Chia KM; Liu J
Breast Cancer Res; 2011 Apr; 13(2):R36. PubMed ID: 21457548
[TBL] [Abstract][Full Text] [Related]
27. Activating Immune Recognition in Pancreatic Ductal Adenocarcinoma via Autophagy Inhibition, MEK Blockade, and CD40 Agonism.
Jiang H; Courau T; Borison J; Ritchie AJ; Mayer AT; Krummel MF; Collisson EA
Gastroenterology; 2022 Feb; 162(2):590-603.e14. PubMed ID: 34627860
[TBL] [Abstract][Full Text] [Related]
28. MEK inhibitors activate Wnt signalling and induce stem cell plasticity in colorectal cancer.
Zhan T; Ambrosi G; Wandmacher AM; Rauscher B; Betge J; Rindtorff N; Häussler RS; Hinsenkamp I; Bamberg L; Hessling B; Müller-Decker K; Erdmann G; Burgermeister E; Ebert MP; Boutros M
Nat Commun; 2019 May; 10(1):2197. PubMed ID: 31097693
[TBL] [Abstract][Full Text] [Related]
29. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
[TBL] [Abstract][Full Text] [Related]
30. MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer.
Hew KE; Miller PC; El-Ashry D; Sun J; Besser AH; Ince TA; Gu M; Wei Z; Zhang G; Brafford P; Gao W; Lu Y; Mills GB; Slingerland JM; Simpkins F
Clin Cancer Res; 2016 Feb; 22(4):935-47. PubMed ID: 26482043
[TBL] [Abstract][Full Text] [Related]
31. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
Song H; Zhang J; Ning L; Zhang H; Chen D; Jiao X; Zhang K
Med Sci Monit; 2018 May; 24():3002-3010. PubMed ID: 29737325
[TBL] [Abstract][Full Text] [Related]
32. MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic-cancer patient-derived orthotopic xenograft (PDOX).
Kawaguchi K; Igarashi K; Murakami T; Kiyuna T; Lwin TM; Hwang HK; Delong JC; Clary BM; Bouvet M; Unno M; Hoffman RM
Oncotarget; 2017 Jul; 8(29):47490-47496. PubMed ID: 28537897
[TBL] [Abstract][Full Text] [Related]
33. CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary.
Xue Y; Meehan B; Macdonald E; Venneti S; Wang XQD; Witkowski L; Jelinic P; Kong T; Martinez D; Morin G; Firlit M; Abedini A; Johnson RM; Cencic R; Patibandla J; Chen H; Papadakis AI; Auguste A; de Rink I; Kerkhoven RM; Bertos N; Gotlieb WH; Clarke BA; Leary A; Witcher M; Guiot MC; Pelletier J; Dostie J; Park M; Judkins AR; Hass R; Levine DA; Rak J; Vanderhyden B; Foulkes WD; Huang S
Nat Commun; 2019 Feb; 10(1):558. PubMed ID: 30718512
[TBL] [Abstract][Full Text] [Related]
34. Concomitant BET and MAPK blockade for effective treatment of ovarian cancer.
Jing Y; Zhang Z; Ma P; An S; Shen Y; Zhu L; Zhuang G
Oncotarget; 2016 Jan; 7(3):2545-54. PubMed ID: 26575423
[TBL] [Abstract][Full Text] [Related]
35. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-211 Modulates the DUSP6-ERK5 Signaling Axis to Promote BRAF
Lee B; Sahoo A; Sawada J; Marchica J; Sahoo S; Layng FIAL; Finlay D; Mazar J; Joshi P; Komatsu M; Vuori K; de Jong PR; Ray A; Perera RJ
J Invest Dermatol; 2021 Feb; 141(2):385-394. PubMed ID: 32888955
[TBL] [Abstract][Full Text] [Related]
37. Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.
McNeill RS; Canoutas DA; Stuhlmiller TJ; Dhruv HD; Irvin DM; Bash RE; Angus SP; Herring LE; Simon JM; Skinner KR; Limas JC; Chen X; Schmid RS; Siegel MB; Van Swearingen AED; Hadler MJ; Sulman EP; Sarkaria JN; Anders CK; Graves LM; Berens ME; Johnson GL; Miller CR
Neuro Oncol; 2017 Oct; 19(11):1469-1480. PubMed ID: 28379424
[TBL] [Abstract][Full Text] [Related]
38. Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases.
Sahni JM; Gayle SS; Bonk KL; Vite LC; Yori JL; Webb B; Ramos EK; Seachrist DD; Landis MD; Chang JC; Bradner JE; Keri RA
J Biol Chem; 2016 Nov; 291(45):23756-23768. PubMed ID: 27650498
[TBL] [Abstract][Full Text] [Related]
39. Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models.
Flanigan SA; Pitts TM; Newton TP; Kulikowski GN; Tan AC; McManus MC; Spreafico A; Kachaeva MI; Selby HM; Tentler JJ; Eckhardt SG; Leong S
Clin Cancer Res; 2013 Nov; 19(22):6219-29. PubMed ID: 24045180
[TBL] [Abstract][Full Text] [Related]
40. Targeting enhancer reprogramming to mitigate MEK inhibitor resistance in preclinical models of advanced ovarian cancer.
Liu S; Zou Q; Chen JP; Yao X; Guan P; Liang W; Deng P; Lai X; Yin J; Chen J; Chen R; Yu Z; Xiao R; Sun Y; Hong JH; Liu H; Lu H; Chen J; Bei JX; Koh J; Chan JY; Wang B; Kang T; Yu Q; Teh BT; Liu J; Xiong Y; Tan J
J Clin Invest; 2021 Oct; 131(20):. PubMed ID: 34464356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]